tbuckley/cabot-search huggingface dataset:
Abstract PR06: Reciprocal prostate cancer signaling with its microenvironment mediates castrate-resistant disease progression
Authors: Manisha Tripathi, Srinivas Nandana, Jen-Ming Huang, Manabu Kato, Leland W. K. Chung, Rajeev Mishra, Li Xin, Neil Bhowmick
Journal: Cancer Research (2016)

Abstract Our lab has previously reported that the mouse model knocked out for TGF-beta receptor type II in fibroblasts results in castrate resistance of prostate tissues, mediated by paracrine Wnt signaling. We found that antagonizing androgen signaling leads to Wnt ligand expression by prostatic fibroblasts, interestingly dependent on cell-cell contact. This led us to hypothesize that a juxtacrine action within the stromal compartment was important to the development of castrate resistance. Building upon this observation, we found that Notch signaling was upregulated in prostate cancer associated fibroblasts (CAFs) compared with normal tissue associated fibroblasts (NAFs). Further, inhibition of Notch signaling in CAFs, using DAPT, resulted in decrease in Wnt2b and decreased expression of Notch target genes. Similarly, castration or androgen receptor antagonism (i.e. bicalutamide or enzalutamide) resulted in increased Notch signaling and downstream Wnts 2 and 2b up regulation. The further generation of chimeric tissue recombinant xenografts with human RV1 prostate cancer epithelia with mouse prostate stromal cells with activated Notch signaling, derived from NICD transgenic mice resulted in increased tumor size compared with wild type control stromal recombinants. Conversely, recombinants derived from prostatic fibroblasts having a loss of Notch signaling, from RBPJ-knockout mice, had diminished tumorigenesis, compared to xenografts with the wild type fibroblasts counterpart. In trying to determine the mediator of Wnt-associated paracrine prostate epithelial expansion, we found downstream YAP activation in the RV1 cells. In a reciprocal epithelial-to-fibroblast communication we found that the RV1 cells treated with conditioned media from NICD fibroblasts showed increased IL-6 expression. Conversely, conditioned media from prostate cancer cells increased Notch target gene expression in CAFs, which was blocked upon addition of IL-6 neutralizing antibody. Taken together there is a stromal-derived signaling cascade involving Notch and Wnt ligands, that activates YAP in the epithelia for paracrine IL-6-dependent Notch activity back in the stromal fibroblasts. Critically, disruption of this cross-talk in the fibroblasts can limit the gain of stem features and castrate resistance of the adjacent epithelia in halting lethal progression of prostate cancer. This abstract is also presented as Poster A44. Citation Format: Manisha Tripathi, Srinivas Nandana, Jen-Ming Huang, Manabu Kato, Leland W. K. Chung, Rajeev Mishra, Li Xin, Neil Bhowmick. Reciprocal prostate cancer signaling with its microenvironment mediates castrate-resistant disease progression. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr PR06.
Sleep intervention during breast cancer chemotherapy: Fatigue and sleep disturbances outcomes
Authors: A. M. Berger, S. Agrawal, J. Chamberlain, L. Farr, B. Kuhn, J. Lynch, S. Von Essen
Journal: Journal of Clinical Oncology (2008)

9580 Background: Fatigue and sleep disturbances are the most frequent symptoms reported in association with adjuvant chemotherapy (CTX) for breast cancer. This study examined whether a four-component Individualized Sleep Promotion Plan (ISPP©) sleep intervention (stimulus control, sleep restriction, relaxation therapy, and sleep hygiene) would reduce fatigue associated with CTX for breast cancer. Methods: Women with stages I-IIIA breast cancer who were post-op and scheduled to receive CTX were eligible for this randomized-controlled trial. Prior to initial CTX, sleep intervention participants (SI, n=113) developed an ISPP; which was reinforced and revised at regular intervals. Controls (HEC, n=106) received healthy-eating information and equal time and attention. Data were collected 2 days prior to and 7 days after each CTX, and 30 days after the last CTX. Fatigue was measured by the Piper Fatigue Scale (PFS) and sleep by the Pittsburgh Sleep Quality Index (PSQI). CTX. Mixed model analysis was used. Results: Fatigue (PFS) in both groups increased significantly throughout treatment and returned to prior to treatment levels by day 30; no differences were found between groups at 30 days (p =0.253). Adherence to the ISPP was examined using a within randomization arm comparison (SI). Those with high adherence (70% or >) to the ISPP reported significantly lower fatigue than did those with < 70% adherence over time (p=0.003), prior to, at CTX 3 and 4, and at 30 days (p=0.020 −0.001). Sleep quality (PSQI) was significantly different between the groups over time (p<.049); the intervention improved sleep regardless of adherence rates. Conclusions: When participants begin CTX with lower fatigue and consistently adhere at a rate >70% to the ISPP intervention, they experienced significantly lower fatigue over time. Sleep quality was significantly higher for participants in the SI group. No significant financial relationships to disclose.
Ethics, Emotions, and the Skills of Talking About Progressing Disease With Terminally Ill Adolescents
Authors: Abby R. Rosenberg, Joanne Wolfe, Lori Wiener, Maureen Lyon, Chris Feudtner
Journal: JAMA Pediatrics (2016)

<h3>Importance</h3> For clinicians caring for adolescent patients living with progressive, life-threatening illness, discussions regarding prognosis, goals of care, and treatment options can be extremely challenging. While clinicians should respect and help to facilitate adolescents' emerging autonomy, they often must also work with parents' wishes to protect patients from the emotional distress of hearing bad news. <h3>Observations</h3> We reviewed the ethical justifications for and against truth-telling, and we considered the published ethical and practice guidance, as well as the perspectives of patients, parents, and clinicians involved in these cases. We also explored particular challenges with respect to the cultural context, timing, and content of conversations at the end of adolescents' lives. In most cases, clinicians should gently but persistently engage adolescents directly in conversations about their disease prognosis and corresponding hopes, worries, and goals. These conversations need to occur multiple times, allowing significant time in each discussion for exploration of patient and family values. While truth-telling does not cause the types of harm that parents and clinicians may fear, discussing this kind of difficult news is almost always emotionally distressing. We suggest some "phrases that help" when clinicians strive to deepen understanding and facilitate difficult conversations with adolescents, parents, and other family members. <h3>Conclusions and Relevance</h3> The pediatrician's opportunities to engage in difficult conversations about poor prognosis may be rare, but such conversations can be crucial. These discussions affect how patients live at the end of their lives, how they die, and how their families go on. Improved understanding of basic principles of communication, as well as augmented understanding of patient, family, and clinician perspectives may better enable us to navigate these important conversations.
A Woman With Intellectual Disability, Amenorrhoea, Seizures, and Balance Problems
Authors: Alastair J. C. Hughes, Hannah E. Steele, Angela Pyle, Yvonne Hart, Richard Quinton, Patrick F. Chinnery
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Rapid Cyclosporine Tapering and Isotretinoin Usage after Unrelated Donor Hematopoietic Stem Cell Transplantation in Juvenile Myelomonocytic Leukemia.
Authors: Keon Hee Yoo, Soo Hyun Lee, Ki Woong Sung, Hong Hoe Koo, Hye Lim Jung
Journal: Blood (2004)
Impact of VEGF and CgA as new predictive tools in management of elderly hormone-refractory prostate cancer (HRPC) patients
Authors: I. Carreca, F. Bellomo, S. Burgio, P. D'Alia, D. Piazza, S. Russo, L. Balducci
Journal: Journal of Clinical Oncology (2009)

e16070 Background: Prostate cancer is one of the most frequent malignancy in men of the Western countries. The identification of new predictive factors of drug activity is crucial for elderly cancer patients, who need a particular selection according to prediction of efficacy and safety by pre-treatment parameters. Several prostate cancers show focal neuroendocrine (NE) spots and CgA seems to be associated to NE phenotype both in tissue and in circulation. VEGF expression in NE cells is corelated with clinical characteristics and disease-specific survival. Somatostatin analogues induce a decrease in plasma CgA and could have also anti-angiogenic activity by inhibition of VEGF, bFGF and GH/IGF-I axis. Methods: elderly patients, median age 75 (range: 65–83), were selected for hormone-refractory disease, previously treated with CAB. Serum PSA and plasmatic CgA and VEGF were evaluated in all pts at baseline (T0) and at 4 months (T4) and 8 months (T8) after therapy. Pts were treated with docetaxel 75 mg/m2 every 3 weeks for 6 cycles and octreotide acetate 20 mg administered intramuscularly every 4 weeks until progression. Clinical and biochemical response, progression- free survival and toxicity were also evaluated. A correlation of basal CgA and VEGF with biochemical response, clinical response and clinical benefit was also investigated. Results: Median duration of follow-up was 18 months (range: 8–32). Patients evaluable for response were 22. PSA response rate (RR) was observed in 10/22 (45%); clinical objective RR was 33% (7/22). Clinical benefit was observed in 19/22 pts (86%). Only mild toxicities was observed in both groups. CgA and VEGF were both strongly reduced after therapy. Lower CgA values correlated with clinical benefit, lower VEGF values also correlated with biochemical and clinical response. Conclusions: This combination treatment showed a good toxicity profile. The most relevant data in this study refer to the role of serum CgA and VEGF levels, for prediction of tumour response. If these findings were confirmed, it could be sufficient to measure these markers levels for identification of those HRPC patients who have more probability of obtaining clinical benefit from a docetaxel-based treatment in combination with a somatostatin analogue. No significant financial relationships to disclose.
GW26-e2173 Association of Mean Platelet Volume with Impaired Myocardial Reperfusion and Short-term Mortality in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Authors: Qingjie Chen, Hongmei Lai, Yining Yang, Xiaomei Li, Rui Xu, Hui Zhai, Fen Liu, Bangdang Chen, Qian Zhao, Yitong Ma
Journal: Journal of the American College of Cardiology (2015)
The Impact of Precision Medicine in Diabetes: A Multidimensional Perspective
Authors: Stephen S. Rich, William T. Cefalu
Journal: Diabetes Care (2016)

In his State of the Union address on 20 January 2015, President Barack Obama announced the Precision Medicine Initiative. Although the concept of “precision medicine” has been present for nearly a decade, many interpretations of precision medicine exist. At its core, precision medicine is a model that proposes the custom delivery of health care, with medical practices, testing, decisions, and treatments tailored to the individual patient level (1). Diagnostic tests and therapies are selected on the basis of not only the specific ‘omics signature (e.g., genomics, transcriptomics, methylomics, proteomics, methylomics) but also the specific risk factor profile and health history obtained from the electronic health record.

In March 2015, National Institutes of Health (NIH) Director Collins established a working group to develop a plan for creating and managing a collection of 1 million volunteers to comprise a precision medicine research cohort. On 17 September 2015, Dr. Collins accepted the framework that would establish the Precision Medicine Initiative, which includes providing the support to build the infrastructure for recruitment of the cohort, collection of the health data, banking of specimens, and launching research. This initial effort for precision medicine represents a major commitment of funds from the NIH. In this regard, President Obama allocated $215 million in fiscal year 2016 to support the initiative, and $130 million alone was targeted for the research participant cohort.

Clearly, the Precision Medicine Initiative ushers in a paradigm change in the way we approach patient care. Specifically, it launches a new era of research, technology, and policy in this area, one in which the participant, the health care practitioner, and research merge into an individual-level relationship focused on the maintenance of health and the prevention and treatment of common human diseases. But, given that the editorial team at Diabetes Care desires to provide the most …
Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction
Authors: Fernando J. Martinez, Jørgen Vestbo, Julie A. Anderson, Robert D. Brook, Bartolome R. Celli, Nicholas J. Cowans, Courtney Crim, Mark Dransfield, Sally Kilbride, Julie Yates, David E. Newby, Dennis Niewoehner, Peter M. A. Calverley
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Inhaled corticosteroids have been shown to decrease exacerbations in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Their effects in patients with milder airflow obstruction remain unclear.This was an analysis of exacerbations in the SUMMIT (Study to Understand Mortality and Morbidity) study.In a double-blind, randomized controlled trial, once-daily inhaled placebo, fluticasone furoate (FF; 100 μg), vilanterol (VI; 25 μg), or the combination of FF/VI was administered. The primary outcome was all-cause mortality. Exacerbations of COPD were an additional predefined endpoint. A total of 1,368 centers in 43 countries and 16,485 patients with moderate COPD and heightened cardiovascular risk were included in the study.Compared with placebo, FF/VI reduced the rate of moderate and/or severe exacerbations by 29% (95% confidence interval [CI], 22-35; P < 0.001) and the rate of hospitalized exacerbations by 27% (95% CI, 13-39; P < 0.001). These relative effects were similar regardless of whether subjects had a history of exacerbation in the year before the study or an FEV1 <60% or ≥60% of predicted. The number needed to treat was not influenced by baseline FEV1 but was influenced by the history of exacerbations. FF/VI also reduced the rate of exacerbations treated with corticosteroids alone or with corticosteroids and antibiotics but not the rates of those treated with antibiotics alone.Patients with moderate chronic airflow obstruction experienced a reduction in exacerbations with FF/VI compared with placebo, irrespective of a history of exacerbations or baseline FEV1. Clinical trial registered with www.clinicaltrials.gov (NCT 01313676; GSK Study number 113782).
Moderate alcohol consumption and breast cancer risk
Authors: W. Y. Chen, W. C. Willett, B. Rosner, G. A. Coldtiz
Journal: Journal of Clinical Oncology (2005)

515 Background: Higher levels of alcohol consumption have been associated with breast cancer risk, but studies have been inconclusive on effect of lower levels. Methods: We examined the relationship between alcohol use and breast cancer risk within the Nurses’ Health Study, a prospective cohort of 121,700 registered nurses aged 30–55 in 1976 who update information on cancer risk factors and outcomes through biennial questionnaires. For this analysis, follow-up began in 1980 when the dietary questionnaire was first administered and continued through 2002. Alcohol use was measured by food frequency questionnaires assessing the average frequency of consumption of alcoholic beverages over the past year. Beer, wine, and liquor were assessed separately and updated in 1984, 1986, 1990, 1994, and 1998. Average daily alcohol consumption in grams per day was calculated by multiplying the number of drinks by the average alcohol content (12.8 grams of alcohol per 12 oz serving of beer, 11.0 per 4 oz serving of wine and 14.0 per serving of spirits). Proportional hazards models controlled for age, body mass index, parity, age at first birth, type and duration of postmenopausal hormone use, family history of breast cancer, benign breast disease, type of menopause, and ages at menarche and menopause. Results: Invasive breast cancer was diagnosed among 937 premenopausal and 4746 postmenopausal women with dietary data during the follow-up period. The association between alcohol use and breast cancer risk was seen only among women with postmenopausal breast cancer (RR (95% CI): 1.06 (0.98–1.13) for 0–5 gms/day, 1.14 (1.03–1.26) for 5–9.9 grams/day, 1.15 (1.05–1.26) for 10–19.9 grams/day and 1.41 (1.27–1.57) >=20 gms/day; p for trend < 0.0001), but not premenopausal breast cancer. Although the magnitude of risk was small, there was a statistically significant increased risk of breast cancer at levels of alcohol < 10 gms/day. The elevated risk was also seen mainly among women who developed ER+/PR+ cancers and was not modified by body mass index, postmenopausal hormone use (estrogen alone or combination estrogen/progesterone), or type of alcohol beverage. Conclusions: Even modest levels of alcohol consumption may be associated with breast cancer risk, especiallyER+/PR+ cancers. No significant financial relationships to disclose.
GW26-e0222 Severity of depressive symptoms pre and post-cardiac rehabilitation: A comparison in Brazil, Canada, Colombia, the United States and Venezuela.
Authors: Sherry Grace, Gabriela L. Melo Ghisi, Claudia Victoria Anchique, Briseida Benaim, Francisco Lopez-Jimenez, Artur Haddad Herdy, Jose Medina Inojosa, Carmen M. Terzic, Lisiane Janovik
Journal: Journal of the American College of Cardiology (2015)
GW26-e0990 Coronary and Cerebral Atherosclerosis Assessed by Combined Coronary and Cerebral Angiography
Authors: Xinhan Liu, Qiang Fu, Hongyu Hu, Dapeng Mo, Dezhao Wang, Wei Chen, Ning Ma, Zhongrong Miao, Buxing Chen
Journal: Journal of the American College of Cardiology (2015)
The Value of Combination of Serum L-Kynurenine Level and Expression of Indoleamine 2,3-Dioxygenase mRNA As a Prognostic Factor in Acute Myeloid Leukemia
Authors: Hisashi Tsurumi, Takuro Matsumoto, Yuhei Shibata, Nobuhiko Nakamura, Hiroshi Nakamura, Soranobu Ninomiya, Junichi Kitagawa, Yasuhito Nannya, Masahito Shimizu, Takeshi Hara
Journal: Blood (2015)
CD20, CD22, CD23, but Not CD37 Expression on CD19+ B-Cells Is Altered by Exogenous Factors in a Sub-Population of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL) Patients,
Authors: Robin R Frank, Sucheta Jagan, Laura A Paganessi, Melissa L Larson, Reem Karmali, Parameswaran Venugopal, Stephanie A. Gregory, Kent W Christopherson
Journal: Blood (2011)
The frequency and emergency treatment of food allergies in Dutch school-going children
Authors: B. Flokstra-de Blok, G. van der Meulen, L. Blaas, C. van Ginkel, N. van Huijgevoort, C. Hulskamp, M. Kroeze, J. Lodeweges, E. Roerdink, M. Schat, A. Stel, A. Dubois
Journal: Allergy (2010)
Low Affinity Interaction with CLL B-Cell Receptors Induces Apoptosis by Down-Regulating Mcl-1 and Up-Regulating BimEL.
Authors: Santanu Paul, Rasmi Abu-Helu, Patricia Mongini, Christine N. Metz, Charles C. Chu, Bettie Steinberg, Steven L. Allen, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2007)
Red Cells — Aging Gracefully in the Blood Bank
Authors: Aaron A.R. Tobian, Paul M. Ness
Journal: New England Journal of Medicine (2016)

Since the advent of clinical blood transfusions early in the 20th century, transfusion medicine has evolved dramatically. The findings that anticoagulant and preservative solutions can prevent clotting so that blood could be stored before transfusion substantially enhanced the ease, feasibility, and safety of transfusions (Figure 1).16 These advances permitted the storage of red-cell units for up to 42 days rather than the need to transfuse fresh blood.However, now one of the major controversies regarding transfusion therapy is whether older blood is harmful, owing to a red-cell "storage lesion." In vitro data have shown that red cells that are . . .
GW26-e3978 Regulatory roles of Angiotensin-Converting Enzyme 2 in NOX4 Expression and Oxidative Stress Levels in Kidneys of Apolipoprotein E-Deficient Mice
Authors: Lai-Jiang Chen, Zhen-Zhou Zhang, Hai-Yan Jin, Ying-Le Xu, Ran Xu, Bei Song, Ping-Jin Gao, Gavin Y. Oudit, Jiu-Chang Zhong
Journal: Journal of the American College of Cardiology (2015)
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status?
Authors: Lara Aprile, Luca Puccetti, Sara Galimberti, Antonella Gozzini, Francesca Scarpini, Marzia Defina, Federica De Majo, Claudia Baratè, Anna Sicuranza, Veronica Candi, Barbara Scappini, Donatella Raspadori, Alessandro Gozzetti, Alberto Bosi, Mario Petrini, Monica Bocchia
Journal: Blood (2013)